Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 17/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1972543 | 1.00 | SLC6A4 (0.48) | SLC6A4SLC6A2KCNH2SLC6A3MCHR1 | |
| SCHEMBL12141387 | 1.00 | SLC6A4 (0.48) | SLC6A4SLC6A2KCNH2SLC6A3MCHR1 | |
| Hydrochloric Acid SCHEMBL28302032 | 0.98 | SLC6A4 (0.47) | SLC6A4SLC6A2KCNH2SLC6A3MCHR1 | |
| Hydrochloric Acid SCHEMBL21989907 | 0.98 | SLC6A4 (0.47) | SLC6A4SLC6A2KCNH2SLC6A3MCHR1 | |
| Hydrochloric Acid SCHEMBL21772806 | 0.98 | SLC6A4 (0.47) | SLC6A4SLC6A2KCNH2SLC6A3MCHR1 | |
| SCHEMBL21590701 | 0.98 | SLC6A4 (0.47) | SLC6A4SLC6A2KCNH2SLC6A3MCHR1 | |
| Hydrochloric Acid SCHEMBL29435243 | 0.98 | SLC6A4 (0.47) | SLC6A4SLC6A2KCNH2SLC6A3MCHR1 | |
| SCHEMBL1005036 | 0.88 | SLC6A1 (0.42) | SLC6A4SLC6A2KCNH2SLC6A3CYP2D6 | |
| SCHEMBL7665473 | 0.88 | SLC6A1 (0.42) | SLC6A4SLC6A2KCNH2SLC6A3CYP2D6 | |
| SCHEMBL295900 | 0.87 | GABRA1 (0.39) | SLC6A4SLC6A2KCNH2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. | 2024-09-12 | — | — | US | disclosed |
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230331683-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2023-10-19 | — | — | US | disclosed |
| EP-4010080-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| EP-4219479-A1 | PYRIMIDINE CARBOXAMIDE COMPOUND AND APPLICATION THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023141595-A2 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| EP-0641782-A1 | PROCESS FOR PRODUCING QUINOLONECARBOXYLIC ACID DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1995-03-08 | — | — | EP | disclosed |
| EP-0131839-B1 | QUINOLINE ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 1989-02-01 | — | — | EP | disclosed |
| EP-0132845-B1 | NOVEL 1,8-NAPHTHYRIDINE DERIVATIVES, AND PROCESS FOR PREPARATION THEREOF | Dainippon Pharmaceutical Co., Ltd. (JP) | 1988-04-13 | — | — | EP | disclosed |
| US-4649144-A | Antibacterial 7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid derivatives | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1987-03-10 | — | — | US | disclosed |
| EP-0132845-A2 | Novel 1,8-Naphthyridine derivatives, and process for preparation thereof | Dainippon Pharmaceutical Co., Ltd. (JP) | 1985-02-13 | — | — | EP | disclosed |
| EP-0131839-A1 | Quinoline antibacterial compounds | ABBOTT LABORATORIES (US) | 1985-01-23 | — | — | EP | disclosed |
| EP-0027752-B1 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Société anonyme dite: LABORATOIRE ROGER BELLON (FR) | 1983-12-21 | — | — | EP | disclosed |
| US-4382937-A | Naphthyridine derivatives and their use as anti-bacterials | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1983-05-10 | — | — | US | disclosed |
| US-4341784-A | BACTERICIDES | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1982-07-27 | — | — | US | disclosed |
| EP-0027752-A1 | Naphthyridine derivatives, processes for their preparation and pharmaceutical compositions containing them | Société anonyme dite: LABORATOIRE ROGER BELLON (FR) | 1981-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331683-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | SPNS2, SPCS2, SMN1; SMN2 | SLC6A4 403/4885SLC6A2 40/4885KCNH2 4398/4885 |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | SLC6A4 3519/4885SLC6A2 2896/4885KCNH2 3956/4885 |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | SLC6A4 3519/4885SLC6A2 2896/4885KCNH2 3956/4885 |
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | SETD2, CARM1, SETDB1 | SLC6A4 4362/4885SLC6A2 3379/4885KCNH2 3596/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | SLC6A4 4859/4885SLC6A2 4863/4885KCNH2 4881/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | SLC6A4 4630/4885SLC6A2 4135/4885KCNH2 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.